Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this study, we examined the extent to which the competing risk of hepatic decompensation influences the benefit of HCC surveillance by investigating the impact of availability of liver transplantation (LTx) and the rate of progression of hepatic decompensation on survival gain from HCC surveillance. A multistate Markov model was constructed simulating a cohort of 50-year-old patients with compensated cirrhosis. The primary outcome of interest was all-cause and HCC-specific mortality. The main input data included incidence of HCC, sensitivity of screening test, and mortality from hepatic decompensation. Treatment modalities modeled included LTx, resection, and radiofrequency ablation. In the base case scenario, LTx would be available to prevent death in a certain proportion of patients. In the absence of surveillance, 68.2% of the cohort members died within 15 years; of these decedents, 25.1% died from HCC and 43.6% died from hepatic decompensation. With surveillance, the median survival improved from 10.4 years to 11.2 years. The number of subjects under surveillance needed to reduce one all-cause and one HCC-specific death over 15 years was 28 and 18, respectively. In sensitivity analyses, incidence of HCC and progression of cirrhosis had the strongest effect on the benefit of surveillance, whereas LTx availability had a negligible effect. CONCLUSION: HCC surveillance decreases all-cause and tumor-specific mortality in patients with compensated cirrhosis regardless of LTx availability. In addition, incidence of HCC and sensitivity of surveillance test also had a substantial impact on the benefits of surveillance. (Hepatology 2018;68:78-88).
Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this study, we examined the extent to which the competing risk of hepatic decompensation influences the benefit of HCC surveillance by investigating the impact of availability of liver transplantation (LTx) and the rate of progression of hepatic decompensation on survival gain from HCC surveillance. A multistate Markov model was constructed simulating a cohort of 50-year-old patients with compensated cirrhosis. The primary outcome of interest was all-cause and HCC-specific mortality. The main input data included incidence of HCC, sensitivity of screening test, and mortality from hepatic decompensation. Treatment modalities modeled included LTx, resection, and radiofrequency ablation. In the base case scenario, LTx would be available to prevent death in a certain proportion of patients. In the absence of surveillance, 68.2% of the cohort members died within 15 years; of these decedents, 25.1% died from HCC and 43.6% died from hepatic decompensation. With surveillance, the median survival improved from 10.4 years to 11.2 years. The number of subjects under surveillance needed to reduce one all-cause and one HCC-specific death over 15 years was 28 and 18, respectively. In sensitivity analyses, incidence of HCC and progression of cirrhosis had the strongest effect on the benefit of surveillance, whereas LTx availability had a negligible effect. CONCLUSION:HCC surveillance decreases all-cause and tumor-specific mortality in patients with compensated cirrhosis regardless of LTx availability. In addition, incidence of HCC and sensitivity of surveillance test also had a substantial impact on the benefits of surveillance. (Hepatology 2018;68:78-88).
Authors: Stacy Loeb; Edward F Vonesh; E Jeffrey Metter; H Ballentine Carter; Peter H Gann; William J Catalona Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: P R Salvalaggio; G E Felga; B D Guardia; M D Almeida; F L Pandullo; C E Matielo; A Evangelista; L Curvelo; R A Rocco; J A Alves; R F Meirelles; S P M Filho; M B de Rezende; P T Pedroso; L G Diaz; M B Rusi; M M Viveiros; D B Neves Journal: Transplant Proc Date: 2016-09 Impact factor: 1.066
Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote Journal: Lancet Date: 2012-12-10 Impact factor: 79.321
Authors: Hossein Poustchi; Geoffrey C Farrell; Simone I Strasser; Alice U Lee; Geoffrey W McCaughan; Jacob George Journal: Hepatology Date: 2011-12 Impact factor: 17.425
Authors: W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Jeong Hee Yoon; Jeong Min Lee; Dong Ho Lee; Ijin Joo; Ju Hyun Jeon; Su Joa Ahn; Seung-Taek Kim; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon Journal: Liver Cancer Date: 2020-08-06 Impact factor: 11.740
Authors: Vera Yakovchenko; Timothy R Morgan; Edward J Miech; Brittney Neely; Carolyn Lamorte; Sandra Gibson; Lauren A Beste; Heather McCurdy; Dawn Scott; Rachel I Gonzalez; Angela M Park; Byron J Powell; Jasmohan S Bajaj; Jason A Dominitz; Maggie Chartier; David B Ross; Matthew J Chinman; Shari S Rogal Journal: Hepatology Date: 2022-03-17 Impact factor: 17.298
Authors: Edwin J R van Beek; Christiane Kuhl; Yoshimi Anzai; Patricia Desmond; Richard L Ehman; Qiyong Gong; Garry Gold; Vikas Gulani; Margaret Hall-Craggs; Tim Leiner; C C Tschoyoson Lim; James G Pipe; Scott Reeder; Caroline Reinhold; Marion Smits; Daniel K Sodickson; Clare Tempany; H Alberto Vargas; Meiyun Wang Journal: J Magn Reson Imaging Date: 2018-08-25 Impact factor: 4.813
Authors: Ju Dong Yang; Benyam D Addissie; Kristin C Mara; William S Harmsen; Jianliang Dai; Ning Zhang; Nicha Wongjarupong; Hawa M Ali; Hamdi A Ali; Fatima A Hassan; Sravanthi Lavu; Jessica L Cvinar; Nasra H Giama; Catherine D Moser; Katsuyuki Miyabe; Loretta K Allotey; Alicia Algeciras-Schimnich; J Paul Theobald; Melissa M Ward; Mindie H Nguyen; Alex S Befeler; K Rajender Reddy; Myron Schwartz; Denise M Harnois; Hiroyuki Yamada; Sudhir Srivastava; Jo Ann Rinaudo; Gregory J Gores; Ziding Feng; Jorge A Marrero; Lewis R Roberts Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-21 Impact factor: 4.090
Authors: Shari S Rogal; Vera Yakovchenko; Rachel Gonzalez; Angela Park; Lauren A Beste; Karine Rozenberg-Ben-Dror; Jasmohan S Bajaj; Dawn Scott; Heather McCurdy; Emily Comstock; Michael Sidorovic; Sandra Gibson; Carolyn Lamorte; Anna Nobbe; Maggie Chartier; David Ross; Jason A Dominitz; Timothy R Morgan Journal: Cancers (Basel) Date: 2021-05-07 Impact factor: 6.639